Delcath Systems, Inc. (DCTH)

Market Cap	397.69M +2.6%
Revenue (ttm)	90.44M +68.0%
Net Income	561,000
EPS	0.01
Shares Out	34.52M
PE Ratio	855.75
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	42,224
Open	11.49
Previous Close	11.45
Day's Range	11.45 - 11.69
52-Week Range	n/a
Beta	0.53
Analysts	Strong Buy
Price Target	20.79 (+80.47%)
Earnings Date	May 7, 2026

About DCTH

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1988
• Employees: 156
• Stock Exchange: NASDAQ
• Ticker Symbol: DCTH
• Website: https://www.delcath.com

Analyst Summary

According to 6 analysts, the average rating for DCTH stock is "Strong Buy." The 12-month stock price target is $20.79, which is an increase of 80.47% from the latest price.

Price Target

$20.79

(80.47% upside)

Analyst Consensus: Strong Buy